



PATENT
Customer No. 22,852
Attorney Docket No. 08702.0009-01000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
LEONARD et al.) Confirmation No.: 7087
)
Application No.: 09/512,701) Group Art Unit: 1645
)
Filed: February 25, 2000) Examiner: N. M. Minnifield
)
For: USE OF IL-12 ANTAGONISTS IN)
THE TREATMENT OF)
RHEUMATOID ARTHRITIS)

23
Linda
4/29/03

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached Form PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a final action under § 1.311, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in an application, and is accompanied by a certification as specified under § 1.97(e). Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

Each document listed in this Information Disclosure Statement was first cited in a communication from the European Patent Office in a counterpart foreign application,

and this Information Disclosure Statement is being filed within three months of the mailing date of that communication.

Copies of the listed documents are attached.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any additional fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: April 23, 2003

By: Rebecca McNeill
Rebecca M. McNeill
Reg. No. 43,796

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com